Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab versus placebo added to standard therapy for early-onset EGPA with inadequate response to steroid pulse therapy
jRCTs031230675Completed
- Sponsor
- GSK
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing Mepolizumab plus standard therapy with Placebo plus standard therapy (2 arms). Primary endpoint: Primary: successful steroid dose reduction at week 8. Started Mar 2024; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on jRCTs031230675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230675.